EC approves ZTALMY for seizures associated with CDKL5 deficiency

The approval was based on data from the Phase III Marigold double-blind placebo-controlled trial.

RanjithKumar Dharma August 01 2023

The European Commission (EC) has approved Marinus Pharmaceuticals’ ZTALMY (ganaxolone) as an adjunctive treatment for epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged between two and 17 years.

Patients aged 18 years and older may continue with ZTALMY.

ZTALMY oral suspension functions as a neuroactive steroid GABA [gamma-aminobutyric acid] receptor modulator, exhibiting its effects on a well-established brain target known for its anti-seizure properties.

The authorisation follows a positive opinion in May 2023 from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

The approval applies to all 27 member states of the European Union and to Norway, Liechtenstein and Iceland.

The approval from the EC was based on data from the Phase III Marigold double-blind placebo-controlled study, which randomised and treated 101 patients with ZTALMY.

The study attained its primary endpoint by demonstrating a median 30.7% reduction in 28-day major motor seizure frequency compared to a 6.9% median reduction for those receiving a placebo.

Marinus chairman and CEO Scott Braunstein stated: “The approval by the EC represents a significant milestone for children, families and physicians who, until now, have been challenged by the impact of seizures and lack of treatments available for CDD.

“This achievement reflects our organisation’s unwavering commitment to bringing an effective treatment option to individuals living with CDD and we are grateful to all the stakeholders who made the approval possible.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close